RNTX Stock — Rein Therapeutics Inc.: Cash, EV, Pipeline

What they do

We currently have two product candidates in clinical development, LTI-03 and LTI-01, however, due to insufficient funding we have paused development of LTI‑01 for an undetermined period of time and are prioritizing LTI‑03.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.61

Market cap

$52.9M

Cash

$43.6M

Enterprise value

$9.3M

Balance sheet

Cash	$43.6M
Debt	$0.0M
Net cash	$43.6M
Enterprise value	$9.3M
Basic shares	86.3M shares
Fully diluted shares	113.4M shares
Fully diluted market cap	$69.2M
Cash per share	$0.51
Quarterly burn	$8.6M
Cash runway	5.0 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

86.3M

Pre-funded warrants

2.3M

Options

3.5M

RSUs

0.0M

Warrants

9.1M

Converts

0.0M

Conv preferred

12.2M

ESPP reserve

0.0M

FDSO

113.4M

Cap table as of 2026-06-30.

Price history

Loading RNTX daily closes…

Loading price history…

Next catalyst

LTI-03 · Est. Nov 7, 2026 · half midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 7, 2026 Now half midpoint	LTI-03 Phase 2 RENEW trial in IPF (interim data)	Phase 2	IPF ()	2H 2026
Nov 11 - Dec 23 in 12 mo	LTI-03	Phase 2	Idiopathic Pulmonary Fibrosis (IPF)	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

LTI-03

Phase 2 · Active Modality: peptide (caveolin-1 scaffolding-protein-derived; inhaled dry powder)

Partnerships UT System/UTHSCT: exclusive license covering LTI-03 (royalty-bearing; milestone/diligent-commercialization terms)

Indications

Idiopathic pulmonary fibrosis (IPF) (Phase 2)

Catalysts

— Q4 2026

Status note RENEW trial: Phase 2 multi-center, randomized, double-blind, placebo-controlled; first patient dosed Mar 2026; screening began May 2025. EMA orphan drug designation Jan 2026.

LTI-01

Phase 2 · Active Modality: proenzyme

Target plasminogen

Partnerships UT System/UTHSCT: exclusive license covering LTI-01

Indications

Loculated pleural effusion (Phase 2)

Status note Phase 2a dose-ranging and Phase 1b completed. Paused indefinitely while resources are prioritized toward LTI-03; resumption timing uncertain.

Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	LTI-03
Lead indication	Idiopathic Pulmonary Fibrosis (IPF)
Lead phase	Phase 2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06968845	Phase 2	Recruiting	Sponsor	Rein Therapeutics	—	Idiopathic Pulmonary Fibrosis (IPF)	2H 2026 Est. Dec 31, 2026 · PCD + 6 wks (Dec 31-Dec 31)

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Rein Therapeutics on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	4,500,000	+4,500,000	0.22%	2026-08-14
Ikarian Capital	2,950,000	+2,950,000	0.50%	2026-08-14
Great Point Partners	2,575,000	+2,575,000	0.63%	2026-08-14
Stonepine Capital	218,038	+218,038	0.17%	2026-08-17

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

RNTX — Rein Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

RNTX — Rein Therapeutics Inc.